PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18634847-0 2008 TRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivin. Celecoxib 67-76 TNF superfamily member 10 Homo sapiens 0-5 18634847-7 2008 Taken together, in malignant glioma survivin is a key regulator in celecoxib- and TRAIL-celecoxib-mediated cell death. Celecoxib 88-97 TNF superfamily member 10 Homo sapiens 82-87 17968315-3 2008 Here we report that COX-2-selective celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 (DR5) and cooperate with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), the ligand for DR5, to induce apoptosis in COX-2-positive and -negative cancer cells. Celecoxib 36-45 TNF superfamily member 10 Homo sapiens 135-190 17968315-3 2008 Here we report that COX-2-selective celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 (DR5) and cooperate with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), the ligand for DR5, to induce apoptosis in COX-2-positive and -negative cancer cells. Celecoxib 36-45 TNF superfamily member 10 Homo sapiens 192-197 17693058-9 2007 Treatment of the resistant cells with camptothecin, celecoxib and cisplatin resulted in the downregulation of c-FLIP and caused a synergistic apoptotic effect with TRAIL. Celecoxib 52-61 TNF superfamily member 10 Homo sapiens 164-169 17145853-3 2006 Our previous work has shown that celecoxib induces death receptor 5 expression, resulting in induction of apoptosis and enhancement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Celecoxib 33-42 TNF superfamily member 10 Homo sapiens 135-190 17145853-3 2006 Our previous work has shown that celecoxib induces death receptor 5 expression, resulting in induction of apoptosis and enhancement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Celecoxib 33-42 TNF superfamily member 10 Homo sapiens 192-197 17145853-6 2006 These results thus indicate that c-FLIP down-regulation also contributes to celecoxib-induced apoptosis and enhancement of TRAIL-induced apoptosis, which complements our previous finding that the extrinsic apoptotic pathway plays a critical role in celecoxib-induced apoptosis in human lung cancer cells. Celecoxib 249-258 TNF superfamily member 10 Homo sapiens 123-128 15572759-12 2004 Combination treatment with celecoxib and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induced additional apoptosis. Celecoxib 27-36 TNF superfamily member 10 Homo sapiens 98-103 32433558-6 2020 COX-II inhibitor celecoxib further enhanced TRAILR2 expression in spheroids, likely resulting from increased ER stress, and thereby re-sensitized TRAIL-resistant cell layers to treatment. Celecoxib 17-26 TNF superfamily member 10 Homo sapiens 44-49 32705218-4 2020 We revealed by MTT and western blotting, respectively, that celecoxib (CCB), an NSAID, and 2,5-dimethyl celecoxib (DMC), a non-cyclooxygenase (COX)-2 inhibitor analog of CCB, were able to sensitize TRAIL-resistant HCC cells to TRAIL, implicating a COX-independent mechanism. Celecoxib 60-69 TNF superfamily member 10 Homo sapiens 198-203 32705218-4 2020 We revealed by MTT and western blotting, respectively, that celecoxib (CCB), an NSAID, and 2,5-dimethyl celecoxib (DMC), a non-cyclooxygenase (COX)-2 inhibitor analog of CCB, were able to sensitize TRAIL-resistant HCC cells to TRAIL, implicating a COX-independent mechanism. Celecoxib 60-69 TNF superfamily member 10 Homo sapiens 227-232 32705218-6 2020 The TRAIL sensitization capacity of CCB in TRAIL-resistant HCC cells was abrogated by an ER stress inhibitor. Celecoxib 36-39 TNF superfamily member 10 Homo sapiens 4-9 32705218-6 2020 The TRAIL sensitization capacity of CCB in TRAIL-resistant HCC cells was abrogated by an ER stress inhibitor. Celecoxib 36-39 TNF superfamily member 10 Homo sapiens 43-48 25299780-10 2014 Finally, TRAIL-induced expression of COX-2 was diminished through siRNA targeting c-Rel or NFATc2 and pharmacologic inhibition of COX-2 with celecoxib or siRNA targeting COX-2, enhanced TRAIL apoptosis. Celecoxib 141-150 TNF superfamily member 10 Homo sapiens 9-14 25050836-0 2014 Synergistic effect of celecoxib in tumor necrosis factor-related apoptosis-inducing ligand treatment in osteosarcoma cells. Celecoxib 22-31 TNF superfamily member 10 Homo sapiens 35-90 25050836-7 2014 The results revealed that CXB sensitized TRAIL-resistant MG-63 OS cells to TRAIL-induced apoptosis through downregulation of cellular B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein, caspase-8 and caspase-3. Celecoxib 26-29 TNF superfamily member 10 Homo sapiens 41-46 25050836-7 2014 The results revealed that CXB sensitized TRAIL-resistant MG-63 OS cells to TRAIL-induced apoptosis through downregulation of cellular B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein, caspase-8 and caspase-3. Celecoxib 26-29 TNF superfamily member 10 Homo sapiens 75-80 24637636-0 2014 COX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAIL-mediated apoptosis. Celecoxib 29-38 TNF superfamily member 10 Homo sapiens 69-74 24637636-7 2014 Finally, celecoxib increases the apoptotic activity of TRAIL. Celecoxib 9-18 TNF superfamily member 10 Homo sapiens 55-60 20394499-0 2010 Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells. Celecoxib 22-31 TNF superfamily member 10 Homo sapiens 35-40 20394499-3 2010 In search of cancer therapeutics that can overcome TRAIL resistance, we show here that celecoxib and camptothecin can sensitize TRAIL-resistant HCC cell lines, HepG2 and Hep3B, to TRAIL-induced apoptosis through downregulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein (c-FLIP) and cleavage of caspase-8 and caspase-3 in the HCC cells. Celecoxib 87-96 TNF superfamily member 10 Homo sapiens 51-56 20394499-3 2010 In search of cancer therapeutics that can overcome TRAIL resistance, we show here that celecoxib and camptothecin can sensitize TRAIL-resistant HCC cell lines, HepG2 and Hep3B, to TRAIL-induced apoptosis through downregulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein (c-FLIP) and cleavage of caspase-8 and caspase-3 in the HCC cells. Celecoxib 87-96 TNF superfamily member 10 Homo sapiens 128-133 20394499-3 2010 In search of cancer therapeutics that can overcome TRAIL resistance, we show here that celecoxib and camptothecin can sensitize TRAIL-resistant HCC cell lines, HepG2 and Hep3B, to TRAIL-induced apoptosis through downregulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein (c-FLIP) and cleavage of caspase-8 and caspase-3 in the HCC cells. Celecoxib 87-96 TNF superfamily member 10 Homo sapiens 128-133